Explore more publications!

Massachusetts Healthcare Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Healthcare Journal.

Press releases published on November 28, 2025

Boehringer Ingelheim announces appointment to Board of Managing Directors
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Kane Biotech Announces Third Quarter 2025 Financial Results
L’Agence des médicaments du Canada émet une recommandation positive pour le remboursement de SKYRIZI® (risankizumab) pour le traitement de la colite ulcéreuse, et AbbVie conclut une lettre d’intention avec l’Alliance pharmaceutique pancanadienne
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
Shriners Hospitals for Children Canada and Children’s Hospital at LHSC launch landmark research program to advance care in rare childhood bone disorders
Les Hôpitaux Shriners pour enfants Canada et l’Hôpital pour enfants du Centre des sciences de la santé de London lancent un programme de recherche historique pour faire progresser les soins liés aux maladies osseuses rares chez l’enfant
Results of the Votes of the  Combined Shareholders’ General Meeting of November 27, 2025
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions